Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine

Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomen...

Descripción completa

Detalles Bibliográficos
Autores principales: Manickam, Agaath Hedina, Buture, Alina, Tomkins, Esther, Ruttledge, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365535/
https://www.ncbi.nlm.nih.gov/pubmed/34430000
http://dx.doi.org/10.1002/ccr3.4625
_version_ 1783738727568244736
author Manickam, Agaath Hedina
Buture, Alina
Tomkins, Esther
Ruttledge, Martin
author_facet Manickam, Agaath Hedina
Buture, Alina
Tomkins, Esther
Ruttledge, Martin
author_sort Manickam, Agaath Hedina
collection PubMed
description Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments.
format Online
Article
Text
id pubmed-8365535
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83655352021-08-23 Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine Manickam, Agaath Hedina Buture, Alina Tomkins, Esther Ruttledge, Martin Clin Case Rep Case Reports Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments. John Wiley and Sons Inc. 2021-08-16 /pmc/articles/PMC8365535/ /pubmed/34430000 http://dx.doi.org/10.1002/ccr3.4625 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Manickam, Agaath Hedina
Buture, Alina
Tomkins, Esther
Ruttledge, Martin
Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
title Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
title_full Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
title_fullStr Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
title_full_unstemmed Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
title_short Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
title_sort raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365535/
https://www.ncbi.nlm.nih.gov/pubmed/34430000
http://dx.doi.org/10.1002/ccr3.4625
work_keys_str_mv AT manickamagaathhedina raynaudsphenomenonsecondarytoerenumabinapatientwithchronicmigraine
AT buturealina raynaudsphenomenonsecondarytoerenumabinapatientwithchronicmigraine
AT tomkinsesther raynaudsphenomenonsecondarytoerenumabinapatientwithchronicmigraine
AT ruttledgemartin raynaudsphenomenonsecondarytoerenumabinapatientwithchronicmigraine

Ejemplares similares